We are live on
!
Find out more
WVP
Worth Venture Partners Portfolio holdings
AUM
$31.6M
1-Year Est. Return
28.5%
This Fund
S&P 500
This Quarter
Est. Return
+6.87%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$184M
AUM Growth
-$21.4M
(-10%)
Cap. Flow
-$46.6M
Cap. Flow
% of AUM
-25.37%
Top 10 Holdings %
Top 10 Hldgs %
35.95%
Holding
217
New
29
Increased
61
Reduced
33
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$5.09M |
| 2 |
GSI Technology
GSIT
|
+$2.17M |
| 3 |
Annovis Bio
ANVS
|
+$1.48M |
| 4 |
Clene
CLNN
|
+$1.45M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$1.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adtran
ADTN
|
+$4.21M |
| 2 |
Silicom
SILC
|
+$2.81M |
| 3 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$2.59M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$2.17M |
| 5 |
Carvana
CVNA
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.84% |
| 2 | Healthcare | 16.62% |
| 3 | Financials | 6.45% |
| 4 | Real Estate | 2.82% |
| 5 | Consumer Staples | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
PUT
Barclays
BCS
$92.7B
| $10.6K | 0.01% |
51,300
+35,300
| +221% | +$273K |
|
127
PUT
Wayfair
W
$11.2B
| $9.68K | 0.01% |
35,000
-5,900
| -14% | -$249K |
|
128
PUT
Carnival Corporation Ltd
CCL
$38.1B
| $8.77K | ﹤0.01% |
175,400
+38,300
| +28% | +$448K |
|
129
PUT
Southwest Airlines
LUV
$22B
| $7.68K | ﹤0.01% |
23,400
-3,900
| -14% | -$122K |
|
130
CALL
Novartis
NVS
$297B
| $7.08K | ﹤0.01% |
+10,900
| New | +$1.09M |
|
|
MDRX
131
PUT
DELISTED
Veradigm Inc. Common Stock
MDRX
| $6.28K | ﹤0.01% |
27,900
+8,400
| +43% | +$102K |
|
132
PUT
Arcus Biosciences
RCUS
$3.55B
| $4.09K | ﹤0.01% |
10,900
-1,800
| -14% | -$34.3K |
|
|
X
133
PUT
DELISTED
US Steel
X
| $3.3K | ﹤0.01% |
+11,800
| New | +$275K |
|
134
CALL
uniQure
QURE
$3.03B
| $1.91K | ﹤0.01% |
+54,600
| New | +$1.03M |
|
135
PUT
GSK
GSK
$104B
| $1.66K | ﹤0.01% |
33,200
+7,700
| +30% | +$276K |
|
|
GES
136
PUT
DELISTED
Guess Inc
GES
| $1.18K | ﹤0.01% |
11,800
-19,900
| -63% | -$383K |
|
137
CALL
Aclaris Therapeutics
ACRS
$726M
| – | – |
-25,600
| Closed | -$1.28K |
|
|
138
Adtran
ADTN
$689M
| – | – |
-265,692
| Closed | -$4.21M |
|
|
APLS
139
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-19,200
| Closed | -$44.5K |
|
140
CALL
BridgeBio Pharma
BBIO
$15.7B
| – | – |
-25,600
| Closed | -$39.7K |
|
141
BioCardia
BCDA
$12.3M
| – | – |
-8,373
| Closed | -$246K |
|
142
BioMarin Pharmaceuticals
BMRN
$11.6B
| – | – |
-3,239
| Closed | -$315K |
|
143
Bristol-Myers Squibb
BMY
$133B
| – | – |
-12,800
| Closed | -$887K |
|
|
144
PUT
Bristol-Myers Squibb
BMY
$133B
| – | – |
-12,800
| Closed | -$1.28K |
|
|
145
Carvana
CVNA
$68.6B
| – | – |
-997,980
| Closed | -$1.95M |
|
146
Equity Residential
EQR
$24.9B
| – | – |
-4,682
| Closed | -$281K |
|
147
Highwoods Properties
HIW
$3.65B
| – | – |
-8,700
| Closed | -$202K |
|
148
PUT
Herbalife
HLF
$1.29B
| – | – |
-22,200
| Closed | -$11.1K |
|
149
PUT
IMAX
IMAX
$2.62B
| – | – |
-14,900
| Closed | -$2.3K |
|
|
150
PUT
Microchip Technology
MCHP
$40.3B
| – | – |
-12,400
| Closed | -$18.6K |
|
Similar funds
VL
SP
OGC
PE
RL
AIIC
LGM
SCA
Worth Venture Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Worth Venture Partners held 217 positions worth $184M, down 10% from $205M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Worth Venture Partners withdrew a net $46.6M in Q2 2023, closing 50 positions and reducing 33 holdings. Its most notable exit was Adtran, an estimated $4.21M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Worth Venture Partners opened a new position in GSI Technology worth $2.76M.
- Worth Venture Partners's largest Q2 2023 buy was GSI Technology: 499,400 shares worth $2.76M.
- Worth Venture Partners added most to Microchip Technology in Q2 2023, an estimated $5.09M increase.
- Worth Venture Partners's biggest Q2 2023 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $2.59M.
- Worth Venture Partners fully exited Adtran in Q2 2023, selling an estimated $4.21M.
- Worth Venture Partners's ten largest holdings make up 36% of its $184M portfolio in Q2 2023.
- Worth Venture Partners opened 29 new positions and closed 50 in Q2 2023.
- Worth Venture Partners's portfolio value fell 10% quarter-over-quarter to $184M.
Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.